



Press release

## **YPOG advises lead investor Vesalius Biocapital on Series C financing round of HepaRegeniX**

**Berlin, July 17, 2024** – YPOG advised the lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds also participated in the investment.

HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its launch in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). This substance has the potential to significantly support liver regeneration in patients with liver metastases or primary liver tumors.

The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.

### **Team**

Dr. Martin Schaper (Lead, Transactions), Partner, Berlin  
Dr. Lutz Schreiber (IP/IT/Data Protection), Partner, Hamburg  
Benjamin Müller (Transactions), Associate, Berlin  
Matthias Treude (IP/IT/Data Protection), Associate, Hamburg  
Cyra Dittberner (Transactions), Associate, Berlin

### **About Vesalius Biocapital IV**

Vesalius Biocapital is an established European life sciences venture capital investor with a long track record of consistent returns, investing in best/first-in-class European Biopharma and HealthTech companies.

The company is investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Its portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.

### **About YPOG**

YPOG is a law firm specialized in tax and business law, active in the core fields of Funds, Tax, Banking + Finance, and Transactions. The team at YPOG represents a broad client base, which ranges from emerging technology companies and family-run SMEs to large corporations, as well as private equity, and venture capital funds. YPOG is one of the leading advisors for venture capital, private equity, and fund structuring in Germany. The firm and its partners have been recognized nationally and internationally by JUVE, Best Lawyers, Legal 500, Focus, Chambers and Partners as well as Leaders League. Today, YPOG has more than 120 experienced lawyers and tax specialists and a notary, in three offices, located in Berlin, Hamburg, and Cologne.

Further information: <http://www.ypog.law> and [www.linkedin.com/company/ypog](http://www.linkedin.com/company/ypog)



**Contact:**

Benno Engelmann  
T +49 172 2749 689 | E [presse@ypog.law](mailto:presse@ypog.law)  
Engelmann Advisory  
[engelmann-advisory.com](http://engelmann-advisory.com)